SBFM · Sunshine Biopharma Inc. · Metrics
Market Cap
$3.27M
Shares
3.88M
Volume · Oct 5
2.13M
Avg daily vol (3M)
520.85K
SBFM metrics
51 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$0.67
Market cap
$3.27M
Price action
20 metricsPrice change (1W)
-20.9%
Price change (30D)
-42.0%
Price change (3M)
-68.4%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
79.0%
Annualized volatility (3M)
80.4%
Beta
—
RSI (14D)
22.5
Price vs SMA 50
-39.9%
Price vs SMA 200
—
Avg volume (3M)
520,853
Relative volume
0.3
Average dollar volume
$637,006
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
3.88M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 1,081.9%
P / book
0.1
reciprocal yield 842.9%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-178.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
30.3%
Operating margin
-16.6%
Trailing 12 months
Net margin
-16.5%
Gross profit (TTM)
$10.71M
Operating profit (TTM)
−$5.89M
Net income (TTM)
−$5.83M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-1.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$35.35M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8,714.2%
Year over year · more shares
Revenue CAGR (3Y)
+102.9%
Revenue CAGR (5Y)
+247.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-21.2%
Return on assets
-17.3%
Debt / equity
—
Current ratio
5.5
EBITDA (TTM)
−$5.54M
Free cash flow (TTM)
—
Quick ratio
3.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$13.75M
Total assets
$33.63M
Total debt
$2.05M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$5.35M
Capital expenditures (TTM)
$19,145
R&D (TTM)
$237,745
SG&A (TTM)
—
Stock compensation (TTM)
$499,397
R&D / revenue
0.7%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
12
13F filer change QoQ
0
Institutional ownership
2.1%
Short interest
3 metricsShort interest
0.6%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
27 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—